New drug tested to keep lung cancer at bay after initial treatment
NCT ID NCT02316002
Summary
This study tested whether the immunotherapy drug pembrolizumab could help prevent lung cancer from coming back in patients who had recently completed treatment for cancer that had spread to only a few other sites. The drug was given by IV every three weeks for up to 16 cycles. The main goal was to see how long patients remained cancer-free after starting this additional treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.